Citadel Advisors
BHVN

Citadel Advisors’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Citadel Advisors’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-5,700
Closed -$862K – 16126
2022
Q3 		$862K Sell
5,700
-15,200
-73% -$2.25M ﹤0.01% 7318
2022
Q2 		$3.04M Sell
20,900
-99,400
-83% -$12.7M ﹤0.01% 4732
2022
Q1 		$14.3M Sell
120,300
-94,900
-44% -$11.8M ﹤0.01% 2431
2021
Q4 		$29.7M Buy
215,200
+30,600
+17% +$3.89M 0.01% 1613
2021
Q3 		$25.6M Buy
184,600
+9,100
+5% +$1.14M 0.01% 1717
2021
Q2 		$17M Sell
175,500
-30,700
-15% -$2.49M ﹤0.01% 2284
2021
Q1 		$14.1M Sell
206,200
-17,800
-8% -$1.44M ﹤0.01% 2465
2020
Q4 		$19.2M Buy
224,000
+127,100
+131% +$10.8M 0.01% 1848
2020
Q3 		$6.3M Buy
96,900
+17,500
+22% +$1.15M ﹤0.01% 2844
2020
Q2 		$5.8M Buy
79,400
+17,400
+28% +$926K ﹤0.01% 2885
2020
Q1 		$2.11M Sell
62,000
-1,500
-2% -$68.6K ﹤0.01% 4057
2019
Q4 		$3.46M Sell
63,500
-14,700
-19% -$728K ﹤0.01% 3589
2019
Q3 		$3.26M Sell
78,200
-41,500
-35% -$1.75M ﹤0.01% 3722
2019
Q2 		$5.24M Buy
119,700
+109,500
+1,074% +$6.17M ﹤0.01% 3012
2019
Q1 		$525K Buy
+10,200
New +$441K ﹤0.01% 6714
2018
Q4 		– Sell
-10,600
Closed -$398K – 10377
2018
Q3 		$398K Sell
10,600
-13,000
-55% -$478K ﹤0.01% 7084
2018
Q2 		$933K Sell
23,600
-80,300
-77% -$2.55M ﹤0.01% 5346
2018
Q1 		$2.68M Buy
+103,900
New +$3.11M ﹤0.01% 3299

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Citadel Advisors's BHVN Position: Q4 2022 in Review

Citadel Advisors sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 185,618 shares — an estimated $28.1M sold.

Citadel Advisors first reported a position in BHVN in Q3 2017 and held it in 21 quarters. The position peaked at $56.6M in Q2 2019. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Citadel Advisors reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Citadel Advisors sold 185,618 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $28.1M.
  • Citadel Advisors first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2017 and held it in 21 quarters.
  • Citadel Advisors's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $56.6M in Q2 2019.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Citadel Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.